Drugs / LX101
LX101
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06196827 | Jul 2022 → Dec 2023 overdue | RPE65-related recessive retinopathy | Innostellar Biotherapeutics Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06212297 | Sep 2023 → Feb 2025 overdue | inherited retinal dystrophy | Innostellar Biotherapeutics Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07054632 | Sep 2023 → Aug 2025 overdue | RPE65-related recessive retinopathy | Innostellar Biotherapeutics Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06024057 | Sep 2023 → Sep 2028 expected | RPE65-related recessive retinopathy | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LX101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06212297 ↗ |
| Known as | rAAV-RPE65 | “Efficacy and Safety of Gene Therapy rAAV-RPE65 (LX101) in Biallelic RPE65 Mutation-associated Inherited Retinal Dystrophy: a Phase III, Multicenter, Randomized Controlled Trial (STAR)” NCT07054632 ↗ |
| Known as | rAAV2-RPE65 | “A Multi-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of rAAV2-RPE65 Gene Therapy (LX101) in Subjects With Biallelic RPE65 Mutation-associated...” NCT06196827 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV2-RPE65 gene therapy” NCT06024057 ↗ |
| Route | Other | “Subretinal administration of LX101 to the study eye” NCT07054632 ↗ |
| Target | RPE65 | “AAV2-RPE65 encoding human RPE65 gene” NCT06024057 ↗ |